Linked Life Data

766762

Source:http://linkedlifedata.com/resource/pubmed/id/766762

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1976-4-10
pubmed:abstractText
Thirty-two patients with psoriatic arthritis unresponsive to conventional therapy were treated wtih the antipyrimidine azaribine. For the group, improvement was highly significant (P less than 0.01) when average painful joint count, ring size, grip strength, pain, and morning gel were compared with baseline measurements. The spectrum of response of individual patients varied from total remission or arthritis in 5 patients to no improvement in 7. Dermatitis improved more than 50% in 26 patients. Reduction in hematocrit, gastrointestinal irritation, and occasional central nervous system toxicity were readily reversed by decreasing or discontinuing dosage. Azaribine appears to be a useful agent for trial in the treatment of refractory psoriatic arthritis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0004-3591
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Treatment of psoriatic arthritis with azaribine.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S.